Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Acetate in African American CRPC Patients
NCT01735396Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Dec 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I) in castration-resistant prostate cancer (CRPC), sponsored by Icahn School of Medicine at Mount Sinai. Started Dec 2012; status: terminated.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01735396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01735396.